Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro
暂无分享,去创建一个
Vincenza Dolo | E. Ricevuto | C. Ficorella | V. Tombolini | S. D'Ascenzo | V. Dolo | Vincenzo Tombolini | G. Gravina | L. Biordi | C. Festuccia | Corrado Ficorella | Enrico Ricevuto | Giovanni Luca Gravina | Sandra D'Ascenzo | Claudio Festuccia | Leda Biordi | S. D’Ascenzo
[1] F. D. De Braud,et al. Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity , 2007, Anti-cancer drugs.
[2] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[3] C. Vicentini,et al. Akt down‐modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors , 2008, The Prostate.
[4] Q. She,et al. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] H. Swaisland,et al. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man , 2004, Xenobiotica; the fate of foreign compounds in biological systems.
[6] P. Chieffi,et al. EPN: A novel epithelial cell line derived from human prostate tissue , 2002, In Vitro Cellular & Developmental Biology - Animal.
[7] S. Steinberg,et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] E. Ricevuto,et al. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma , 2007, The Prostate.
[9] R. Nicholson,et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. , 2004, Endocrine-related cancer.
[10] A. Angelucci,et al. Evaluation of metastatic potential in prostate carcinoma: an in vivo model. , 2004, International journal of oncology.
[11] E. Baldi,et al. Androgen Receptor Expression in Prostate Carcinoma Cells Suppresses α6β4 Integrin-Mediated Invasive Phenotype. , 2000, Endocrinology.
[12] M. Gross,et al. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer , 2007, BMC cancer.
[13] R. Vessella,et al. Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. , 2007, Endocrine-related cancer.
[14] A. Angelucci,et al. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures , 2003, Journal of Cancer Research and Clinical Oncology.
[15] E. Ricevuto,et al. Her2 crosstalks with TrkA in a subset of prostate cancer cells: Rationale for a guided dual treatment , 2009, The Prostate.
[16] L. Seymour,et al. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. , 2003, Clinical Cancer Research.
[17] M. Hidalgo,et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] J. Trapman,et al. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. , 1998, Cancer research.
[19] A. Angelucci,et al. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. , 2005, Endocrine-related cancer.
[20] E. Baldi,et al. EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen‐sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR) , 2004, International journal of cancer.
[21] C. Tepper,et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. , 2002, Cancer research.
[22] Wulfran Cacheux,et al. Impact of IGF‐1R/EGFR cross‐talks on hepatoma cell sensitivity to gefitinib , 2006, International journal of cancer.
[23] B. Esterni,et al. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] J. Manola,et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.
[25] W. Isaacs,et al. Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. , 2006, Experimental cell research.
[26] N. Rosen,et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. , 2001, Cancer research.
[27] M. Kris,et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] Mike Wilson,et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] Noah Craft,et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.
[30] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[31] Stefania Staibano,et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] F. S. French,et al. Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth , 2005, Clinical Cancer Research.
[33] G. Stamp,et al. Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. , 2004, Neoplasia.
[34] D. Leroith,et al. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells , 2004, Oncogene.
[35] R. Bianco,et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. , 2001, Cancer research.
[36] G. Tortora,et al. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] C. Cordon-Cardo,et al. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] M. Motta,et al. Characterization of prostate cancer DU145 cells expressing the recombinant androgen receptor. , 2003, Oncology research.
[39] M. Rubin,et al. A phase II trial of gefitinib in patients with non‐metastatic hormone‐refractory prostate cancer , 2007, BJU international.
[40] M. Loda,et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.
[41] L. Seymour,et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] J. Baselga,et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] G. Tortora,et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] E. Ricevuto,et al. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells. , 2007, Oncology reports.
[45] Ingo K Mellinghoff,et al. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. , 2004, Cancer cell.